Léčba bevacizumabem v kombinaci s karboplatinou a perorálním
vinorelbinem u pacientu s nemalobunečnym karcinomem plic
(NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno

J 2019

Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Marcela TOMÍŠKOVÁ; Lenka JAKUBÍKOVÁ; Jana ŠPELDOVÁ et al.

Základní údaje

Originální název

Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno

Název anglicky

Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno

Autoři

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Marcela TOMÍŠKOVÁ; Lenka JAKUBÍKOVÁ; Jana ŠPELDOVÁ; Bohdan KADLEC; Ondřej VENCLÍČEK; Monika BRATOVÁ; Andrea BENEJOVÁ a Zdeněk MERTA

Vydání

Studia pneumologica et phthiseologica, Praha, Trios s.r.o. 2019, 1213-810X

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Scopus

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00110660

Organizační jednotka

Lékařská fakulta

EID Scopus

2-s2.0-85071030604

Klíčová slova česky

pokročilý nemalobuněčný karcinom plic; léčba; bevacizumab; orální vinorelbin

Klíčová slova anglicky

Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 4. 2020 16:27, Mgr. Tereza Miškechová

Anotace

ORIG EN

V originále

For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.

Anglicky

Citovat

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Marcela TOMÍŠKOVÁ; Lenka JAKUBÍKOVÁ; Jana ŠPELDOVÁ; Bohdan KADLEC; Ondřej VENCLÍČEK; Monika BRATOVÁ; Andrea BENEJOVÁ a Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno. Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, roč. 79, č. 3, s. 88-94. ISSN 1213-810X.

@article{1555856,
   author = {Skřičková, Jana and Chloupková, Renata and Tomíšková, Marcela and Jakubíková, Lenka and Špeldová, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Bratová, Monika and Benejová, Andrea and Merta, Zdeněk},
   article_location = {Praha},
   article_number = {3},
   keywords = {Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment},
   language = {cze},
   issn = {1213-810X},
   journal = {Studia pneumologica et phthiseologica},
   title = {Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno},
   url = {https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d},
   volume = {79},
   year = {2019}
}

TY  - JOUR
ID  - 1555856
AU  - Skřičková, Jana - Chloupková, Renata - Tomíšková, Marcela - Jakubíková, Lenka - Špeldová, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Bratová, Monika - Benejová, Andrea - Merta, Zdeněk
PY  - 2019
TI  - Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno
JF  - Studia pneumologica et phthiseologica
VL  - 79
IS  - 3
SP  - 88-94
EP  - 88-94
PB  - Trios s.r.o.
SN  - 1213810X
KW  - Advanced non-small cell lung cancer
KW  - Bevacizumab
KW  - Carboplatin
KW  - Oral vinorelbine
KW  - Treatment
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d
L2  - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d
N2  - For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.
ER  -

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Marcela TOMÍŠKOVÁ; Lenka JAKUBÍKOVÁ; Jana ŠPELDOVÁ; Bohdan KADLEC; Ondřej VENCLÍČEK; Monika BRATOVÁ; Andrea BENEJOVÁ a Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno. \textit{Studia pneumologica et phthiseologica}. Praha: Trios s.r.o., 2019, roč.~79, č.~3, s.~88-94. ISSN~1213-810X.

Přehled o publikaci